



## **DNAe to Present New Data on G-BSI Blood-to-Result Test for Rapid Identification of Bloodstream Infections at AMP 2016**

**London, UK and Carlsbad, CA, USA – 9 November 2016** – DNA Electronics ('DNAe'), the inventors of semiconductor-based next-generation DNA sequencing (NGS) technology, announces that Vice President, Product Management, Dr Meghan Norvell, will present new data on the rapid detection of bloodstream infections directly from whole human blood samples at the Association for Molecular Pathology (AMP) 2016 Annual Meeting, in Charlotte, NC.

Dr Steve Allen, CEO DNAe Group Holdings said: "AMP 2016 is a greatly respected conference and an ideal place for us to present data on our complete end-to-end workflow for the first time. This includes bacterial, fungal and antibiotic resistance gene targets at low limits of detection. Our Genalysis® platform for serious bloodstream infections (G-BSI) detects and identifies pathogens directly from whole human blood".

"Referred to as a 'national epidemic' in the US, the human cost of sepsis is enormous: there are over 1 million cases in the US each year, and 28-50% of people with severe sepsis will die. A key factor is the speed at which a patient receives the appropriate antibiotics, with the chance of mortality increasing 7.6% every hour that a patient in septic shock does not receive the correct treatment. Compared to current tests, which can take up to three days, G-BSI will enable a turnaround time of just a few hours, addressing a huge and urgent unmet need."

### **Details of Poster Presentation:**

**Title:** 'Rapid, Sensitive Detection of Clinical Bloodstream Infections Directly from Whole Human Blood'

**Location:** Infectious Diseases poster session, Exhibit Hall

**Poster number:** ID67

**Presenter:** Dr Meghan Norvell, with Senior Scientist, Dr Cathal McElgunn

**Time:** Saturday 12 November, 9:45 am - 10:45 am

DNAe's G-BSI test uses a combination of novel technologies, including ultra-sensitive sample preparation to remove the time-consuming blood culture step, and semiconductor-based real time PCR for rapid pathogen detection. This allows the test to identify the most prevalent causes of bloodstream infections and key antibiotic resistance markers within just a few hours of sample presentation. The test can be performed by non-specialist laboratory personnel and simply requires a standard 10 mL blood collection tube containing the sample to be slotted into a cartridge, which is then inserted into the instrument.

Regius Professor Chris Toumazou, Founder and Executive Chairman, DNAe Group Holdings, said: "This data will demonstrate both the great progress being made in the development of our G-BSI test, and the suitability of DNAe's semiconductor-based DNA analysis technology for the diagnosis of sepsis, where time to result is a critical factor in reducing mortality. This is a testament to the platform, the team and the strategy we have in place to revolutionise how serious bloodstream infections are diagnosed and treated."

The AMP 2016 Annual Meeting takes place from 10-12 October. To meet Dr Meghan Norvell or Dr Cathal McElgunn at the event, please email [contact@dnae.com](mailto:contact@dnae.com).

— Ends —

### **About DNAe – [www.dnae.com](http://www.dnae.com)**

DNAe is commercialising its pioneering semiconductor DNA analysis technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling early administration of appropriate treatment.

In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics, Inc.), a developer of a novel and highly sensitive system for rapid isolation of rare cells in the bloodstream. DNAe is developing a complete sample to result genomic analysis platform combining DNA Electronics Inc.'s Pathogen Capture System with its own Genalysis® semiconductor DNA analysis technology. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. DNAe's first product will be a diagnostic test for bloodstream infections for use in the management and prevention of sepsis. In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to \$51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.

A private company, with operations in London, UK, and Carlsbad, CA and Washington, DC, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting-edge life sciences companies.

## **Contact Details**

### **DNAe**

Professor Chris Toumazou, Chairman  
Dr Steve Allen, Chief Executive Officer (London, UK)

Tel: +44 (0)20 7036 2100

### **Instinctif Partners (media relations)**

Sue Charles / Jen Lewis / Alex Bannister

Tel: +44 (0)20 7457 2020

Email: [DNAe@instinctif.com](mailto:DNAe@instinctif.com)